Eptotermin Alfa

Summary

Eptotermin Alfa (CHEMBL2108594) is an approved protein (ATC M05BC02); indicated across 4 conditions including bone disorder and tibia fracture.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: M05BC02
• Indications: 4 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108594
Name	Eptotermin Alfa
Type	Protein
Max phase	4
ATC	M05BC02

Also known as: Bmp-7, Bone morphogenetic protein 7, Eptotermin alfa, Eptotermina alfa, Eptotermine alfa, Hbmp7, Opgenra, Osigraft, Osteogenic protein 1, Rh-polypeptide-52, EPTOTERMIN ALFA

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	Bone morphogenetic protein receptors	Agonist

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bone disorder	4	MONDO:0005381	EFO:0004260
tibia fracture	4	MONDO:0005320	EFO:0003944
spondylolisthesis	4	MONDO:0008475	EFO:0007493

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
osteoarthritis, knee	2	MONDO:0005416	EFO:0004616

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01111045	PHASE2	COMPLETED	Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee
NCT01133613	PHASE1	COMPLETED	Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).